Lenalidomide: Clinical Trials

682 trials of Lenalidomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

312 completed, 87 terminated, 82 recruiting, 77 active not recruiting. 682 Phase 2, 174 Phase 1, 13 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2682Completed 312, Terminated 87, Recruiting 82, Active not recruiting 77, Unknown 68, Withdrawn 28, Not yet recruiting 25, Enrolling by invitation 2, Suspended 1
Phase 1174Completed 83, Terminated 26, Active not recruiting 19, Recruiting 16, Unknown 15, Withdrawn 10, Not yet recruiting 4, Suspended 1
Phase 313Completed 4, Recruiting 3, Not yet recruiting 2, Unknown 2, Terminated 1, Withdrawn 1

Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide

Trials (filtered) newest first · largest first

All 682 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)742027-04-202026-11-18
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory
Phase 2Not yet recruitingOlivia Newton-John Cancer Research Institute252027-01-012026-11-03
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM)
Phase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in Oncology9202026-12-232026-10-22
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC4702026-12-132026-11-05
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma
Phase 1 / Phase 2Not yet recruitingUniversitätsklinikum Hamburg-Eppendorf2202026-12-012026-05-20
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL)
Phase 2Not yet recruitingThe Lymphoma Academic Research Organisation552026-12-012026-09-10
Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2Not yet recruitingSun Yat-sen University292026-12-012026-11-16
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Lenalidomide, Bruton's tyrosine kinase inhibitor, Chidamide - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences872026-11-012026-11-04
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China242026-10-152026-10-26
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China102026-10-012026-09-18
Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
Zanubrutinib, Lenalidomide - Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib
Phase 2RecruitingXiaohui Ren332026-09-252026-11-10
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL)
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China242026-09-152026-09-18
A Open-Label Phase in Participants With Multiple Myeloma
Dexamethasone, IBI3003, Lenalidomide - Multiple Myeloma
Phase 2Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.1202026-08-152026-08-14
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
Lenalidomide, Targeted Therapy, Immune Checkpoint Inhibitors - Hepatocellular Carcinoma (HCC)
Phase 2RecruitingShunda Du322026-08-122026-09-21
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide - Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Phase 2Not yet recruitingMassachusetts General Hospital1602026-08-012026-06-23
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma
Phase 2WithdrawnUNC Lineberger Comprehensive Cancer Center2026-07-012026-06-09
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
Polatuzumab Vedotin, Rituximab (R), Zanubrutinib - Large B-Cell Lymphoma (LBCL)
Phase 2Not yet recruitingRuijin Hospital1122026-06-302026-07-21
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM)
Phase 2 / Phase 3WithdrawnRegeneron Pharmaceuticals2026-06-052026-06-18
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
QLS4131, QL2109, Pomalidomide - Malignant Plasma Cell Neoplasms
Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.1622026-06-012026-05-01
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
Polatuzumab Vedotin, rituximab, Cyclophosphamide - Large B-Cell Lymphoma (LBCL)
Phase 2Not yet recruitingRuijin Hospital1782026-05-062026-05-19

Showing 20 of 682. Sign in to see all of them.

Conditions studied

Multiple Myeloma (253)  ·  Lymphoma, Large B-Cell, Diffuse (71)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (58)  ·  Recurrence (50)  ·  Lymphoma, Follicular (46)  ·  Lymphoma (43)  ·  Lymphoma, Mantle-Cell (37)  ·  Neoplasms, Plasma Cell (37)  ·  Myelodysplastic Syndromes (32)  ·  Lymphoma, Non-Hodgkin (29)  ·  Lymphoma, B-Cell, Marginal Zone (27)  ·  Leukemia (23)  ·  Leukemia, Myeloid, Acute (18)  ·  Lymphoma, B-Cell (17)  ·  Waldenstrom Macroglobulinemia (12)

Sponsors

M.D. Anderson Cancer Center (45)  ·  National Cancer Institute (NCI) (26)  ·  Celgene (23)  ·  Mayo Clinic (21)  ·  Memorial Sloan Kettering Cancer Center (19)  ·  Celgene Corporation (16)  ·  Ruijin Hospital (13)  ·  H. Lee Moffitt Cancer Center and Research Institute (12)  ·  The First Affiliated Hospital with Nanjing Medical University (11)  ·  Dana-Farber Cancer Institute (10)  ·  Weill Medical College of Cornell University (10)  ·  Institute of Hematology & Blood Diseases Hospital, China (9)  ·  Arbeitsgemeinschaft medikamentoese Tumortherapie (7)  ·  Peking Union Medical College Hospital (7)  ·  University Health Network, Toronto (7)

Countries

United States (386)  ·  China (85)  ·  France (64)  ·  Germany (47)  ·  Italy (46)  ·  Spain (44)  ·  Canada (32)  ·  United Kingdom (32)  ·  Sweden (20)  ·  Australia (19)  ·  Austria (19)  ·  Denmark (19)  ·  South Korea (18)  ·  Belgium (16)  ·  Greece (16)

Top investigators

Hani Hassoun, MD (4)  ·  Ravi Vij, M.D. (4)  ·  Robert Knight, MD (4)  ·  Shaji K. Kumar, MD (4)  ·  Bruno Carneiro de Medeiros (3)  ·  Craig B. Reeder, MD (3)  ·  Evangelos Terpos, Prof (3)  ·  Felicitas Hitz, MD (3)  ·  Liren Qian, PhD (3)

Results publications

PMID 29358183, PMID 33357481, PMID 39319495, PMID 23834234, PMID 35285981, PMID 35549810, PMID 26181891, PMID 27531679, PMID 32325490, PMID 34182226, PMID 34826409, PMID 35132679, PMID 35952327, PMID 38649340, PMID 38652812, PMID 17021321, PMID 17893227, PMID 17989313, PMID 18161005, PMID 18334676, PMID 18606983, PMID 18824593, PMID 18987358, PMID 19118065, PMID 19182205, PMID 19705057, PMID 19720904, PMID 20385792, PMID 20508619, PMID 20651074, PMID 20724537, PMID 21051557, PMID 21228334, PMID 21495023, PMID 21504290, PMID 21551228, PMID 21596852, PMID 21630308, PMID 21719884, PMID 21725050, PMID 21812019, PMID 21937701, PMID 22033493, PMID 22058200, PMID 22241792, PMID 22354206, PMID 22422823, PMID 22495176, PMID 22504925, PMID 22517904

NIH funding

2023 (15), P30CA015083 (14), 2009 (10), 2008 (6), 2015 (6), U10CA180821 (5), 2019 (4), 2025 (4), P30CA014599 (4), P30CA015704 (4), U10CA031946 (4), U10CA032102 (4), U10CA180888 (4), 2017 (3), P30CA016672 (3)